Searched for
RYBELSUS
Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...- Novo rebrands diabetes pill as Ozempic to tap blockbuster nameNovo Nordisk is relaunching a diabetes tablet as Ozempic in the United States. This move aims to boost sales by using the strong brand reco...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...
- Future diabetes care seen leaning towards GLP-1 drugsThe diabetes treatment landscape in India is on the brink of transformation. Innovative GLP-1 medications are set to redefine therapy stand...
- HC seeks Novo Nordisk's reply on Natco plea to revoke patentThe Delhi High Court has asked Novo Nordisk to explain why its patent for the diabetes and weight loss drug semaglutide should not be cance...
- Delhi HC allows Sun Pharma to manufacture, export its own weight loss drugThe Delhi High Court has allowed Sun Pharma to manufacture and export its version of semaglutide, the diabetes and anti-obesity drug made b...
- Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatmentThe joint studies showed some improvement in a few biological measures of the disease, but most of the changes were small and not enough to...
- Novo Nordisk slashes Wegovy prices in India by up to 37% to boost sluggish sales of weight-loss drugAccording to renowned endocrinologist Dr Shashank Joshi, a steep cut in the prices of Wegovy will help improve access and affordability. “B...
- Weight-loss therapy goes pill-to-shot with higher efficacy, convenienceSales of Novo Nordisk’s oral weight-loss drug Rybelsus have plateaued as Indians increasingly shift to injectable GLP-1 drugs like Eli Lill...
- Eli Lilly plans to launch experimental weight-loss pill in India, says executiveLilly's orforglipron is designed to mimic the appetite-suppressing GLP-1 hormone targeted by the company's blockbuster injection tirzepatid...
- Food Chained: How weight-loss drugs are changing India’s eating habits and forcing restaurants to take noteNew diabetes and obesity drugs, like Mounjaro and Ozempic, are changing people's relationships with food. While these drugs help control di...
- Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 monthsThe drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-...
- Novo Nordisk's Wegovy, Mounjaro sales in India double on month in JulySales of Novo Nordisk's Wegovy and Eli Lilly's Mounjaro in India doubled in July, according to Pharmarack data. Wegovy, launched in June, s...
- Shedding weight may no longer be a prickly issue as Eli Lilly’s weight-loss pill moves closer to launchEli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participant...
- India's anti-obesity drug market has grown more than fourfold in the last five yearsIndia's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven by lifestyle di...
- India’s anti-obesity drug market quadruples in five years on lifestyle disease surgeIndia's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025. Semaglutide pill Ryb...
- New study warns of serious side effects from popular weight loss drugs Wegovy and Ozempic, finds they may paralyse stomachA recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis, characterize...
- New oral diabetes + obesity drug's India sales surge 100%India experiences a surge in Rybelsus sales, impacting the anti-obesity market. Semaglutide dominates, reflecting India's obesity challenge...
- What's behind the scramble for semaglutide?The global demand for the diabetes medicine Ozempic, containing semaglutide, is causing shortages in several countries due to its off-label...
Load More
